AIMS/HYPOTHESIS: We have previously shown that the association of integrin-associated protein (IAP) with tyrosine phosphatase non-receptor type substrate-1 (SHPS-1) regulates the response of cells, including osteoclasts, osteoblasts, smooth muscle and retinal endothelial cells, to IGF-I. Here we sought to: (1) determine whether the regulation of IGF-I responsiveness by the association of IAP with SHPS-1 is a generalised response of endothelial cells; (2) identify the mechanism by which this association contributes to changes in endothelial cell responses to IGF-I; and (3) determine whether inhibition of this association alters pathophysiological changes occurring in vivo. METHODS: Endothelial cells were maintained in 5 mmol/l glucose and at hyperglycaemic levels, and exposed to an anti-IAP antibody that disrupts the association between IAP and SHPS-1. A rodent model of diabetes with endothelial cell dysfunction was used to investigate the role of the association of IAP with SHPS-1 in endothelial cell function in vivo. RESULTS: Endothelial cells maintained in 5 mmol/l glucose showed constitutive cleavage of the extracellular domain of IAP (which contains the SHPS-1 binding site), with no association between IAP and SHPS-1 being detected. In contrast, hyperglycaemia inhibited IAP cleavage, allowing IAP to associate with SHPS-1 and IGF-I to stimulate SHPS-1 tyrosine phosphorylation. Exposure to the anti-IAP antibody inhibited IGF-I-stimulated tube formation and increased permeability. In the rodent model, basal IAP-SHPS-1 association was not detected in retinal extracts from normal rats, but was fully restored in rats with diabetes. The anti-IAP antibody inhibited the association of IAP with SHPS-1, and reduced retinal vascular permeability and leucocyte adherence to levels similar to those in non-diabetic rats. The antibody also significantly inhibited the aberrant neovascularisation induced by hypoxia. CONCLUSIONS/ INTERPRETATION: Our results demonstrate that the increased association of IAP with SHPS-1 contributes to the pathophysiological changes in the endothelium that are induced by hyperglycaemia and hypoxia.
AIMS/HYPOTHESIS: We have previously shown that the association of integrin-associated protein (IAP) with tyrosine phosphatase non-receptor type substrate-1 (SHPS-1) regulates the response of cells, including osteoclasts, osteoblasts, smooth muscle and retinal endothelial cells, to IGF-I. Here we sought to: (1) determine whether the regulation of IGF-I responsiveness by the association of IAP with SHPS-1 is a generalised response of endothelial cells; (2) identify the mechanism by which this association contributes to changes in endothelial cell responses to IGF-I; and (3) determine whether inhibition of this association alters pathophysiological changes occurring in vivo. METHODS: Endothelial cells were maintained in 5 mmol/l glucose and at hyperglycaemic levels, and exposed to an anti-IAP antibody that disrupts the association between IAP and SHPS-1. A rodent model of diabetes with endothelial cell dysfunction was used to investigate the role of the association of IAP with SHPS-1 in endothelial cell function in vivo. RESULTS: Endothelial cells maintained in 5 mmol/l glucose showed constitutive cleavage of the extracellular domain of IAP (which contains the SHPS-1 binding site), with no association between IAP and SHPS-1 being detected. In contrast, hyperglycaemia inhibited IAP cleavage, allowing IAP to associate with SHPS-1 and IGF-I to stimulate SHPS-1tyrosine phosphorylation. Exposure to the anti-IAP antibody inhibited IGF-I-stimulated tube formation and increased permeability. In the rodent model, basal IAP-SHPS-1 association was not detected in retinal extracts from normal rats, but was fully restored in rats with diabetes. The anti-IAP antibody inhibited the association of IAP with SHPS-1, and reduced retinal vascular permeability and leucocyte adherence to levels similar to those in non-diabeticrats. The antibody also significantly inhibited the aberrant neovascularisation induced by hypoxia. CONCLUSIONS/ INTERPRETATION: Our results demonstrate that the increased association of IAP with SHPS-1 contributes to the pathophysiological changes in the endothelium that are induced by hyperglycaemia and hypoxia.
Authors: M B Grant; R N Mames; C Fitzgerald; K M Hazariwala; R Cooper-DeHoff; S Caballero; K S Estes Journal: Diabetes Care Date: 2000-04 Impact factor: 19.112
Authors: L E Smith; W Shen; C Perruzzi; S Soker; F Kinose; X Xu; G Robinson; S Driver; J Bischoff; B Zhang; J M Schaeffer; D R Senger Journal: Nat Med Date: 1999-12 Impact factor: 53.440
Authors: Christoph W Spraul; A Baldysiak-Figiel; Gerhard K Lang; Gabriele E Lang Journal: Graefes Arch Clin Exp Ophthalmol Date: 2002-02-22 Impact factor: 3.117
Authors: Bruce A Berkowitz; Robin Roberts; Hongmei Luan; Jamie Peysakhov; Xianzhi Mao; Kenneth A Thomas Journal: Invest Ophthalmol Vis Sci Date: 2004-07 Impact factor: 4.799
Authors: Laura A Maile; Walker H Busby; Katherine A Gollahon; William Flowers; Nikol Garbacik; Stefani Garbacik; Kara Stewart; Timothy Nichols; Dwight Bellinger; Amit Patel; Paul Dunbar; Matt Medlin; David Clemmons Journal: Endocrinology Date: 2014-08-29 Impact factor: 4.736
Authors: Xinchun Shen; Gang Xi; Laura A Maile; Christine Wai; Clifford J Rosen; David R Clemmons Journal: Mol Cell Biol Date: 2012-08-06 Impact factor: 4.272
Authors: Laura A Maile; Katherine Gollahon; Christine Wai; Paul Dunbar; Walker Busby; David Clemmons Journal: J Diabetes Res Date: 2014-10-20 Impact factor: 4.011
Authors: Katie-May McLaughlin; Denisa Bojkova; Joshua D Kandler; Marco Bechtel; Philipp Reus; Trang Le; Florian Rothweiler; Julian U G Wagner; Andreas Weigert; Sandra Ciesek; Mark N Wass; Martin Michaelis; Jindrich Cinatl Journal: Curr Issues Mol Biol Date: 2021-09-22 Impact factor: 2.976